Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.60 |
| ▸ | SQLE | Q14534 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | FNTA | P49354 | 1/20 | 0.53 |
| ▸ | FNTB | P49356 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532264 | 1.00 | KMT2A (0.68) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL29645142 | 1.00 | KMT2A (0.68) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL2852929 | 0.98 | KMT2A (0.73) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL1527772 | 0.98 | KMT2A (0.73) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL2852926 | 0.98 | KMT2A (0.73) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| Acetaldehyde SCHEMBL27515440 | 0.93 | KMT2A (0.60) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL7299167 | 0.83 | KMT2A (0.73) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL7354471 | 0.83 | KMT2A (0.73) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL23802597 | 0.81 | KMT2A (1.00) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| Squalene SCHEMBL21823197 | 0.81 | KMT2A (1.00) | KMT2AALOX15MEN1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0360760-B1 | Pipecolic acid containing cyclopeptolides, their preparation and pharmaceutical compositions containing them | SANDOZ AG (CH) | 1995-02-15 | — | — | EP | claimed |
| WO-2021069686-A1 | NOVEL THERAPEUTIC COMBINATIONS COMPRISING DERIVATIVES OF OXAZAPHOSPHORINES FOR THE TREATMENT OF CANCER | INSTITUT GUSTAVE ROUSSY (FR) | 2021-04-15 | — | — | WO | disclosed |
| EP-3143032-A1 | NOVEL DERIVATIVES OF OXAZAPHOSPHORINES AND THERAPEUTIC USES THEREOF | Institut Gustave Roussy (FR) | 2017-03-22 | — | — | EP | disclosed |
| WO-2015173367-A1 | NOVEL DERIVATIVES OF OXAZAPHOSPHORINES AND THERAPEUTIC USES THEREOF | INSTITUT GUSTAVE ROUSSY (FR) | 2015-11-19 | — | — | WO | disclosed |
| CN-104955952-A | Lna oligonucleotide carbohydrate conjugates | SANTARIS PHARMA AS | 2015-09-30 | — | — | CN | disclosed |
| US-8354092-B2 | Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2468734-A1 | Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry | Siemens Medical Solutions USA, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-1854877-B1 | Process for the deacylation of cyclic lipopeptides | ASTELLAS PHARMA INC (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100317842-A1 | Development of Molecular Imaging Probes for Carbonic Anhydrase-IX Using Click Chemistry | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7829063-B2 | Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-5376634-A | Microbiocides | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-27 | — | — | US | disclosed |
| US-5356931-A | Use of α-arylacrylic derivatives for controlling pests | BASF AKTIENGESELLSCHAFT (DE) | 1994-10-18 | — | — | US | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0382185-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1994-06-15 | — | — | EP | disclosed |
| US-5298527-A | Insecticides | BASF AKTIENGESELLSCHAFT (DE) | 1994-03-29 | — | — | US | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| EP-0486011-A2 | Pharmaceutical composition against Pneumocystis carinii | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-20 | — | — | EP | disclosed |
| EP-0462531-A2 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-27 | — | — | EP | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317842-A1 | Development of Molecular Imaging Probes for Carbonic Anhydrase-IX Using Click Chemistry | CA9, CA4, CA13 | KMT2A 1041/4885ALOX15 2992/4885MEN1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.